Current guideline recommendations include various combinations of targeted therapy with immunotherapy.
Panelists discuss how recent FDA regulatory actions regarding obeticholic acid have raised concerns about its long-term safety profile and accessibility, leading health care teams to develop strategies for supporting patients through treatment transitions while navigating insurance coverage and access challenges for newer primary biliary cholangitis (PBC) therapies.
A novel collaboration between the University of Pennsylvania and US Anesthesia Partners is working to drive evidence-based change in benzodiazepine use.
Recent FDA findings highlight that a major ingredient in popular cold fighters, phenylephrine, may not offer genuine relief.
These agents are likely to become the mainstay of cancer treatment in the very near future.
For patients with type 1 and type 2 diabetes, decisions around the selection of glucose meters can be difficult as there are several brands and types of meters available.
Factor XI inhibitors show promise as a safer alternative to direct oral anticoagulants for preventing and treating thrombosis, offering similar efficacy with reduced bleeding risk.
Evidence indicates that up to 25% of all prescriptions for children could be dosed inappropriately, making it the most common type of medication administration error.
Therapeutic drug monitoring is essential with tacrolimus, which is one of the key immunosuppressive agents used after solid organ transplant.
Outpatient treatment is primarily based on patient-specific factors, whereas oseltamivir remains the therapy of choice for inpatient settings.
Pharmacists are in a strong position to identify the early warning signs of diabetes because they are often the most accessible and frequently visited members of the health care team.
Integration of these agents requires supportive care considerations for cytokine release syndrome, neurotoxicity, infection, and antigen-specific toxicities to ensure optimal care of patients with multiple myeloma receiving T-cell–engaging therapies.
Evidence-based guidelines support the safe and effective administration of Ig therapy in clinical practice.
Their expertise complements multidisciplinary teams in a variety of clinical settings.
In this retrospective study, investigators evaluated a pharmacy-led initiative in the emergency department (ED), finding a potential reduction in ED revisits and hospital readmissions, though results were not statistically significant.
Cases discuss triglyceride levels, supplement use, and more.
Precise, more potent therapy can offer reduced toxicity.
IMROZ study data show Isa-VRd may be a new standard of care.
Pharmacists are uniquely positioned to interact with patients who may be seeking an OTC drug or supplement as first-line therapy for short sleep duration.
National Asthma and Allergy Awareness Month highlights how pharmacists in all health care settings are in a unique position to improve management and outcomes of individuals with these conditions.
Pharmacists serve as advocates to optimize patient pharmaceutical care, advance the profession, and positively influence the community.
The drug may be a risk factor for dementia-related illnesses.
Pharmacists can heighten awareness about cardiovascular health and promote heart-healthy lifestyles.
Pharmacists can navigate career paths through passion, adaptability, and patient-centered soft skills.
Biosimilar therapeutic interchange processes can mitigate high costs of cancer drugs.
Medication therapy management reimbursement can be a driving factor to work toward statin implementation in this patient group.
Multiple preparatory steps are involved in creating a delicious meal. Planning, preparation, and revision are similarly important in building a successful residency research program.